Scientists are increasingly investigating retatrutide, a promising drug from Eli Lilly, as a potential advance in weight management. Distinct from many previous approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, chemicals that affect hunger and blood sugar … Read More